EP Patent

EP4319749A1 — Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Assigned to F Hoffmann La Roche AG · Expires 2024-02-14 · 2y expired

What this patent protects

Combination therapies comprising belvarafenib and cobimetinib and comprising belvarafenib, cobimetinib, and atezolizumab are provided for the treatment of melanoma carrying a NRAS mutation.

USPTO Abstract

Combination therapies comprising belvarafenib and cobimetinib and comprising belvarafenib, cobimetinib, and atezolizumab are provided for the treatment of melanoma carrying a NRAS mutation.

Drugs covered by this patent

Patent Metadata

Patent number
EP4319749A1
Jurisdiction
EP
Classification
—
Expires
2024-02-14
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.